Search

Displaying results 4491 - 4500 of 5504 in total
  1. Drug

    RGX-111

    go.drugbank.com/drugs/DB17632
    Investigational

    Developed by REGENXBIO Inc., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46666]

  2. Drug

    SM-1997

    go.drugbank.com/drugs/DB18670
    Experimental

    [A261816] It is under investigation for the treatment of cutaneous sulfur mustard-induced injury.

  3. Drug

    Tulisokibart

    go.drugbank.com/drugs/DB18719
    Investigational

    It is being investigated for ulcerative colitis.

  4. Drug

    Metribolone

    go.drugbank.com/drugs/DB02998
    Experimental

    It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.

  5. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacri...

  6. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    It is being developed by Vitae Pharmaceuticals.

  7. Drug

    XmAb 2513

    go.drugbank.com/drugs/DB06324
    Investigational

    It has been investigated for the treatment of hodgkin’s lymphoma.

  8. Drug

    Poloxalene

    go.drugbank.com/drugs/DB11451
    InvestigationalVet approved

    It belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).

  9. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.

  10. Drug

    Ravagalimab

    go.drugbank.com/drugs/DB16676
    Investigational

    Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis